SOP Guide for Pharma

BA-BE Studies: SOP for Selectivity and Sensitivity Evaluation – V 2.0

Auditor

BA-BE Studies: SOP for Selectivity and Sensitivity Evaluation – V 2.0

Standard Operating Procedure for Selectivity and Sensitivity Evaluation in BA/BE Method Validation

Department BA-BE Studies
SOP No. SOP/BA-BE/180/2025
Supersedes SOP/BA-BE/180/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a standardized procedure for evaluating the selectivity and sensitivity of analytical methods used in bioavailability/bioequivalence (BA/BE) studies for accurate quantification of analytes in biological matrices.

2. Scope

This SOP applies to all LC-MS/MS methods developed and validated in the bioanalytical laboratory for BA/BE studies to ensure accurate detection of analytes without interference and to establish the lower limit of quantification (LLOQ).

3. Responsibilities

  • Analyst: Prepares and analyzes blank and spiked samples from multiple plasma sources.
  • Study Supervisor: Reviews data and evaluates method performance for selectivity and sensitivity.
  • QA Officer: Ensures compliance of documented procedures with ICH M10 and FDA guidelines.
See also  BA-BE Studies: SOP for Monitoring Vital Signs During Clinical Phase - V 2.0

4. Accountability

The Head of Bioanalytical Operations is accountable for ensuring appropriate validation of selectivity and sensitivity across plasma sources, as part of the regulatory submission dossier.

5. Procedure

5.1 Selectivity Evaluation

  1. Obtain blank plasma samples from at least six independent sources, including:
    • Four normal plasma samples
    • One lipemic sample
    • One hemolyzed sample
  2. Process blank plasma samples without internal standard or analyte.
  3. Process additional samples spiked with analyte at LLOQ concentration and internal standard.
  4. Inject all samples using validated LC-MS/MS method.
  5. Evaluate chromatograms for interfering peaks at the retention times of analyte and IS.

5.2 Acceptance Criteria for Selectivity

  1. Response in blank sample must be less than 20% of the response in LLOQ for analyte and less than 5% for IS.
  2. At least 5 out of 6 plasma lots must comply with these criteria.
  3. Record results in Annexure-1: Selectivity Evaluation Log.
See also  BA-BE Studies: SOP for Clinical Trial Material Storage at Site - V 2.0

5.3 Sensitivity Evaluation

  1. Prepare and analyze six replicates of LLOQ samples from a single plasma lot.
  2. Inject samples along with a fresh calibration curve.
  3. Measure signal-to-noise (S/N) ratio and back-calculated concentration for each replicate.
  4. Evaluate method capability to detect and quantify the LLOQ accurately.

5.4 Acceptance Criteria for Sensitivity

  1. LLOQ response must be at least 5 times the baseline noise.
  2. Precision (%CV) should be ≤20% and accuracy within ±20% of nominal.
  3. Document S/N ratios and replicate results in Annexure-2: Sensitivity Evaluation Summary.

5.5 Documentation and Reporting

  1. Compile chromatograms, response tables, %CV and %Nominal values for all replicates.
  2. Prepare validation summary including selectivity and sensitivity conclusions.
  3. Submit report to QA for approval and file with method validation documents.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • LC-MS/MS: Liquid Chromatography with Tandem Mass Spectrometry
  • IS: Internal Standard
  • LLOQ: Lower Limit of Quantification
  • %CV: Percent Coefficient of Variation

See also  BA-BE Studies: SOP for Study Initiation Checklist - V 2.0

7. Documents

  1. Selectivity Evaluation Log – Annexure-1
  2. Sensitivity Evaluation Summary – Annexure-2

8. References

  • ICH M10: Bioanalytical Method Validation
  • US FDA Guidance for Industry: Bioanalytical Method Validation (2022)
  • Internal Method Validation SOP

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Selectivity Evaluation Log

Plasma Lot Type Analyte Response in Blank % of LLOQ Response Status
PL-101 Normal 150 12% Accepted
PL-106 Hemolyzed 240 18% Accepted

Annexure-2: Sensitivity Evaluation Summary

Replicate No. Measured Conc. (ng/mL) % Nominal S/N Ratio Status
1 4.8 96% 6.5 Accepted
2 5.2 104% 7.0 Accepted

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial Issue New SOP QA Head
17/04/2025 2.0 Updated plasma lot requirements, annexures added ICH M10 Update QA Head
Exit mobile version